At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 843 enrolled
Drug / intervention
Peficitinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-label Extension Study in Rheumatoid Arthritis Patients Who Have Completed Phase 2b Study or Phase 3 Study of ASP015K
In Brief
A Phase 3 clinical trial evaluating Peficitinib for Arthritis, Rheumatoid. Completed, enrolled 843 participants across 175 sites in 3 countries.
Detailed Summary
This study evaluated the safety and efficacy of long-term administration of ASP015K in patients who have completed Phase IIb or Phase III studies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Rheumatoid
CountriesJapan, South Korea, Taiwan
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2012
First PostedJul 2012
Primary CompletionSep 2019
TodayJul 2026
First PostedJul 11, 2012
Enrollment StartJun 13, 2012
Primary CompletionSep 30, 2019
TodayJul 2, 2026
Enrollment to primary: 7.3 yearsPosted 14.0 years ago
Interventions
Peficitinibdrug
Oral Tablet